Therapeutic anticancer antibodies
Therapeutic anticancer antibodies
复制标题
DOI：
10.1517/13543776.13.2.177
复制
发表时间：
2003-02
影响因子：
6.6
通讯作者：
S. Murray;H. Linardou
中科院分区：
文献类型：
--
作者：
S. Murray;H. Linardou
在发现产生几乎无限供应的单克隆抗体的技术之后的几年中，已经对它们在恶性疾病的治疗中的用途给予了很多关注。在此期间，我们已经开发了允许检测和刺激恶性细胞的策略，不仅来自血液学恶性肿瘤，而且来自实体瘤，利用幼稚抗体、缀合抗体和设计抗体。随着基因工程的到来，抗体已经以无数方式被操纵，不仅在其特异性方面，而且其药代动力学和药效学也可能被改变。从多年的体内研究发展而来的坚实背景，现在正引领该领域走向光明的未来。在过去几年中，超过20种单克隆抗体（mAb）获得了许可证批准，不仅用于恶性适应症。在这个后基因组时代，多种技术将使我们能够快速识别、鉴定和评估新的靶点。基于抗体的治疗策略有一个不断发展的市场，这不仅体现在药物开发的复兴上，也体现在临床上几种领先的治疗性mAb的惊人结果上。在未来十年内，治疗性抗体会成为肿瘤学家手中的标准工具吗？
In the years following the discovery of techniques to generate a nearly limitless supply of monoclonal antibodies, much attention has been given to their use in the therapy of malignant diseases. During this time we have developed strategies that allow for the detection and also the irradication of malignant cells, not only from haematological malignancies, but also from solid tumours utilising naive, conjugated and designer antibodies. With the arrival of genetic engineering, antibodies have been manipulated in countless ways, not only with respect to their specificity, but their pharmacokinetics and pharmacodynamics may also be altered. A firm background, developed from years of in vivo studies, is now leading the field into a bright future. In the last few years, over 20 monoclonal antibodies (mAbs) have gained licence approval, not only in malignant indications. In this postgenomic era a multitude of technologies will allow us to rapidly identify, characterise and evaluate new targets. There is a developing market for antibody based treatment strategies, as evidenced by the revitalisation, not only of pharmaceutical developments, but also following the spectacular results of several leading therapeutic mAbs in the clinic. Within the next decade will therapeutic antibodies become a standard tool in the hands of the oncologist?